Article Text

P021 Mycoplasma genitalium- testing and treating in a level 2 primary care service
  1. Tamuka Gonah1,
  2. Jodie Scrivener1,
  3. Isata Gando1,
  4. Daniel Richardson2,3
  1. 1Care UK limited, Brighton, UK
  2. 2Brighton and Sussex Medical School, Brighton, UK
  3. 3Brighton and Sussex University Hospitals NHS Trust, Brighton, UK


Introduction Mycoplasma genitalium (MG) is an emerging sexually transmitted infection causing up to 20% cases of urethritis in men and is a cause of PID. Most UK centres do not have access to MG testing. Locally we use an algorithm for testing and management of MG in collaboration with our level 3 service screening men with urethritis and women with PID.

Methods We reviewed the electronic Patient records of patients tested for MG from January 2016 to February 2017.

Results 66 patients were screened, all with genital symptoms. 35(53%) were male. 10/66(15.2%) patients tested positive for MG, 6(9.1%) males and 4(6.1%) females: median age was 34. The clinical symptoms were: 4/66(6.1%) -penile discharge, 4/66(6.1%)-long history of increased vaginal discharge, 1/66(1.5%)-haematospermia, 1/66(1.5%) penile sores. 8/10(80%) were treated with 1st-line treatment (extended course of Azithromycin) in our primary care service while 2/10(20%) were referred to Level 3 service for assessment and treatment. Partner notification was done and documented in 50% of the positive cases but interestingly none of the 10 patients attended for test-of-care as advised.

Discussion We have shown that MG testing and treatment is feasible in a level 2 primary care setting in collaboration with level 3 services and that MG prevalence is high in symptomatic patients using this service.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.